Is amyloid burden measured by 18F-Flutemetamol PET associated with progression in clinical Alzheimer’s disease?

Manuscript Number: 

21-5046R1

Author(s): 
Trine Holt Edwin, Anne-Brita Knapskog, Ebba Gløersen Müller, Mona-Elisabeth Revheim, Caroline Stokke, Bjørn Heine Strand

Disclosures

Trine Holt Edwin

  • Nothing to Disclose

Anne-Brita Knapskog

  • Patents/Royalties
    2016-2019 National coordinator, Boehringer-Ingelheim (1346.0023). 2017-2019 Principal investigator site , Roche (BN29553) 2021-2025 Principal investigator site, Novo Nordisk, EVOKE (NN6535-4730)

Ebba Gløersen Müller

  • Nothing to Disclose

Mona-Elisabeth Revheim

  • Nothing to Disclose

Caroline Stokke

  • Nothing to Disclose

Bjørn Heine Strand

  • Nothing to Disclose